|
22 Jul 2022 |
I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
|
|
21 Jul 2022 |
Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development
|
|
21 Jul 2022 |
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
|
|
21 Jul 2022 |
F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody
|
|
20 Jul 2022 |
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
|
|
20 Jul 2022 |
Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
|
|
19 Jul 2022 |
ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens
|
|
18 Jul 2022 |
Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
|
|
18 Jul 2022 |
EMA Validates Marketing Authorization Application for Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer
|
|
16 Jul 2022 |
HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China
|
|
14 Jul 2022 |
Hemab Therapeutics Presents New Data on HMB-001 for the Treatment of Glanzmann Thrombasthenia and Other Bleeding Disorders at 2022 ISTH Congress
|
|
14 Jul 2022 |
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
|
|
14 Jul 2022 |
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor α for the Treatment of Advanced Solid Tumors
|
|
13 Jul 2022 |
Y-mAbs’ Announces Clearance of IND for GD2-SADA
|
|
12 Jul 2022 |
FDA Accepts Byondis' Biologics License Application for [Vic-] Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer
|
|
12 Jul 2022 |
Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates potential as once monthly treatment for people with haemophilia A
|
|
12 Jul 2022 |
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
|
|
11 Jul 2022 |
Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors
|
|
11 Jul 2022 |
Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis
|
|
09 Jul 2022 |
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
|
|
08 Jul 2022 |
Sobi to license loncastuximab tesirine from ADC Therapeutics
|
|
07 Jul 2022 |
CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer
|
|
07 Jul 2022 |
Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®
|
|
07 Jul 2022 |
SunHo Announces First Patient Dosed in Phase 1/2 Clinical Trial of Two First-in-class Immunocytokines: IAP0971 and IAE0972
|
|
06 Jul 2022 |
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
|
